Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan

被引:0
|
作者
Liu, Ya-Ming [1 ]
Ou, Huang-Tz [2 ]
Yang, Yen-Kuang [3 ]
机构
[1] Natl Cheng Kung Univ, Dept Econ, Tainan 701, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 701, Taiwan
[3] Natl Cheng Kung Univ, Dept Psychiat, Coll Med, Tainan 701, Taiwan
来源
关键词
PHARMACEUTICAL MARKET; PHYSICIAN; IMPACT;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: A health care system in which there is no separation between prescription and dispensation, combined with a regulated prescription drug market, leads to various generic substitution mechanisms for antidepressants. Aims of the Study: We investigated the determinants of generic versus brand-name antidepressant choices in a regulated prescription market where physicians both prescribe and dispense drugs. Methods: Using data from a sample of one million individuals selected randomly from the registry of National Health Insurance beneficiaries in 2010, and all claims for these one million enrollees between January 1997 and December 2011, we employed logistic regression to examine the choice of generic versus brand-name antidepressants in the Taiwanese prescription drug market. Results: Access to various antidepressant brands varies according to the accreditation level and type of ownership of the healthcare provider. Private healthcare providers and those with lower accreditation levels were more likely to prescribe generic antidepressants compared to their brand-name counterparts. The diversity of products and competition in the molecule market was positively associated with the probability of prescribing generic antidepressants. Discussion: In a regulated prescription drug market with no separation between prescription and dispensation, the substitution of generic antidepressant prescriptions in place of brand-name prescriptions is likely driven by drug and provider market characteristics, rather than by lowering costs. Implications for Healthcare Provision: The allocation of different types of ownership and accreditation levels of healthcare providers may lead to unequal access to various brands of antidepressants. Implications for Health Policies: Policies for improving the treatment of depression should take into account the structure of molecule and provider markets as important factors in determining the choice and utilization of antidepressants, in a healthcare system where physicians both prescribe and dispense drugs. Implications for Future Research: Other psychotropic drug classes should be investigated to explore the effect of molecule and provider characteristics on the utilization of various classes of medication.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 50 条
  • [21] Generic versus brand-name cardiovascular drugs: a remarkable update
    Flacco, Maria Elena
    Fragassi, Giorgia
    Manzoli, Lamberto
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2015, 12 (04)
  • [22] A primer on brand-name prescription drug reimbursement in the United States
    Hernandez, Inmaculada
    Hung, Anna
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (01): : 99 - 106
  • [23] Continuing trends in US brand-name and generic drug competition
    Grabowski, Henry
    Long, Genia
    Mortimer, Richard
    Bilginsoy, Mehmet
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 908 - 917
  • [24] A drug by any other name ... generic and brand-name drugs are clinically equivalent
    Morgan, Steven G.
    JOURNAL OF PRIMARY HEALTH CARE, 2015, 7 (02) : 93 - 93
  • [25] Uncertainty in the generic versus brand name prescription decision
    Jörgen Hellström
    Niklas Rudholm
    Empirical Economics, 2010, 38 : 503 - 521
  • [26] Uncertainty in the generic versus brand name prescription decision
    Hellstrom, Jorgen
    Rudholm, Niklas
    EMPIRICAL ECONOMICS, 2010, 38 (03) : 503 - 521
  • [27] Generic versus Brand-Name North American Topical Glaucoma Drops
    Mammo, Z.
    Flanagan, J. G.
    James, D. F.
    Trope, G. E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [28] Generic versus brand-name North American topical glaucoma drops
    Mammo, Zaid N.
    Flanagan, John G.
    James, David F.
    Trope, Graham E.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2012, 47 (01): : 55 - 61
  • [29] STAKEHOLDER PERSPECTIVE Payers' Approaches to Generic versus Brand-Name Medications
    Jacobs, Michael S.
    AMERICAN HEALTH AND DRUG BENEFITS, 2010, 3 (02): : 134 - 134
  • [30] The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs
    Borgherini, G
    CLINICAL THERAPEUTICS, 2003, 25 (06) : 1578 - 1592